BR0313469A - Forma galêmica para a liberação cólica de princìpios ativos - Google Patents

Forma galêmica para a liberação cólica de princìpios ativos

Info

Publication number
BR0313469A
BR0313469A BR0313469-5A BR0313469A BR0313469A BR 0313469 A BR0313469 A BR 0313469A BR 0313469 A BR0313469 A BR 0313469A BR 0313469 A BR0313469 A BR 0313469A
Authority
BR
Brazil
Prior art keywords
pectin
galemic
colic
release
aqueous solution
Prior art date
Application number
BR0313469-5A
Other languages
English (en)
Inventor
Sandrine Bourgeois
Elias Fattal
Antoine Andremont
Patrick Couvreur
Original Assignee
Ct Nat La Rech Scient C N R S
Da Volterra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0210151A external-priority patent/FR2843301B1/fr
Application filed by Ct Nat La Rech Scient C N R S, Da Volterra filed Critical Ct Nat La Rech Scient C N R S
Publication of BR0313469A publication Critical patent/BR0313469A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

"FORMA GALêNICA PARA A LIBERAçãO CóLICA DE PRINCìPIOS ATIVOS". A presente invenção refere-se a formas galênicas multiparticulares aptas a serem utilizadas por via oral e destinadas ao combate da cólica, de princípios ativos escolhidos no grupo que compreende as enzimas capazes de inativar os macrolídeos e similares, as enzimas capazes de inativarem as quinolonas e as <225>-lactamases.
BR0313469-5A 2002-08-09 2003-08-06 Forma galêmica para a liberação cólica de princìpios ativos BR0313469A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0210151A FR2843301B1 (fr) 2002-08-09 2002-08-09 Forme galenique pour la delivrance colique de principes actifs
FR0213514A FR2843302B1 (fr) 2002-08-09 2002-10-29 Forme galenique pour la delivrance colique de principes actifs
PCT/FR2003/002474 WO2004016248A2 (fr) 2002-08-09 2003-08-06 Forme galenique pour la delivrance colique de principes actifs

Publications (1)

Publication Number Publication Date
BR0313469A true BR0313469A (pt) 2005-07-12

Family

ID=30772009

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313469-5A BR0313469A (pt) 2002-08-09 2003-08-06 Forma galêmica para a liberação cólica de princìpios ativos

Country Status (14)

Country Link
US (2) US7485294B2 (pt)
EP (2) EP1992336A3 (pt)
JP (1) JP2006500359A (pt)
KR (1) KR101080577B1 (pt)
CN (1) CN1681480B (pt)
AT (1) ATE432066T1 (pt)
AU (1) AU2003274229B2 (pt)
BR (1) BR0313469A (pt)
CA (1) CA2495291A1 (pt)
DE (1) DE60327772D1 (pt)
ES (1) ES2327630T3 (pt)
FR (1) FR2843302B1 (pt)
MX (1) MXPA05001607A (pt)
WO (1) WO2004016248A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694145B2 (ja) * 2004-05-17 2011-06-08 株式会社 メドレックス 経口腸溶性製剤
JP2008529996A (ja) * 2005-02-09 2008-08-07 ダ・ボルテラ 活性因子の大腸送達
CN101257892B (zh) * 2005-05-18 2013-01-02 达沃尔泰拉公司 吸附剂的结肠递送
WO2006129386A1 (ja) * 2005-06-03 2006-12-07 Medrx Co., Ltd. 経口腸溶性医薬組成物
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
GB0714226D0 (en) * 2007-07-20 2007-08-29 Therapeutics Ltd E anti-bacterial combination therapy
WO2009037264A2 (en) * 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
GB0719771D0 (en) * 2007-10-10 2007-11-21 Therapeutics Ltd E Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
GB0813211D0 (en) 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
FR2950252B1 (fr) * 2009-09-23 2012-01-20 Centre Nat Rech Scient Forme galenique capable d'adsorber de maniere specifique les molecules indesirables
BR112012021275B1 (pt) 2010-02-23 2021-07-27 Da Volterra Formulação compreendendo um adsorvente misturado com carragenina, para entrega oral e liberação controlada de adsorventes no intestino, e, uso de uma formulação
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP3132033B1 (en) 2014-04-17 2019-10-30 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
JP6803328B2 (ja) 2014-08-28 2021-01-06 シンセティック バイオロジクス,インコーポレイテッド 大腸菌ベースでのベータラクタマーゼ生産
JP6672277B2 (ja) 2014-10-08 2020-04-01 シンセティック・バイオロジクス・インコーポレイテッド ベータラクタマーゼ製剤およびその使用
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
CA2977385C (en) 2015-02-23 2024-04-09 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
EP3265119B1 (en) 2015-03-06 2023-10-11 Theriva Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
US10182993B2 (en) 2015-04-06 2019-01-22 Patheon Softgels Inc. Compositions for colonic delivery of drugs
ES2922009T3 (es) 2016-02-23 2022-09-06 Da Volterra Variantes de beta-lactamasa
US10988749B2 (en) 2016-02-23 2021-04-27 Da Volterra Beta-lactamase variants
CN111511350B (zh) 2017-07-07 2023-10-13 埃皮辛特瑞柯斯公司 用于治疗剂的肠胃外施用的组合物
EP3701022B1 (en) 2017-10-25 2023-03-01 Da Volterra Beta-lactamase variants

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
FR2608456B1 (fr) * 1986-12-18 1993-06-18 Mero Rousselot Satia Microcapsules a base de gelatine et de polysaccharides et leur procede d'obtention
FR2613624B1 (fr) * 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
US4963368A (en) * 1988-04-18 1990-10-16 Nabisco Brands, Inc. Oxidoreductase enzyme stabilized highly unsaturated fatty acids and derivatives of such acids
RU2104084C1 (ru) 1989-02-16 1998-02-10 Бритиш Технолоджи Груп Лимитед Капсула дозируемого выброса
DK0454044T3 (da) * 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
JPH0413741A (ja) * 1990-05-02 1992-01-17 Chisso Corp ペクチン・ポリリシン高分子電解質複合体
JPH0413724A (ja) 1990-05-02 1992-01-17 Chisso Corp 可溶性ポリイミド、その製造法及び液晶配向膜用塗布液
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
FI920206A0 (fi) * 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
DE59303759C5 (de) * 1992-01-17 2009-04-09 Alfatec-Pharma Gmbh Wirkstoff-enthaltende festkörper mit einem gerüst aus hydrophilen makromolekülen und verfahren zu ihrer herstellung
US5718969A (en) * 1993-08-25 1998-02-17 Fmc Corporation Nonaggregating hydrocolloid microparticulates, intermediates therefor, and processes for their preparation
WO1997027843A2 (en) * 1996-01-30 1997-08-07 Advanced Polymer Systems, Inc. Targeted delivery of drugs to the lower gastrointestinal tract
PL332669A1 (en) * 1996-10-09 1999-09-27 Givaudan Roure Int Method of obtaining minute beads constituting a food additive
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
IL130303A0 (en) * 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
ATE432066T1 (de) 2009-06-15
FR2843302B1 (fr) 2004-10-22
CA2495291A1 (fr) 2004-02-26
WO2004016248A3 (fr) 2004-04-08
KR101080577B1 (ko) 2011-11-04
MXPA05001607A (es) 2005-09-20
EP1992336A3 (fr) 2009-05-13
JP2006500359A (ja) 2006-01-05
CN1681480A (zh) 2005-10-12
US20050249716A1 (en) 2005-11-10
US20090162339A1 (en) 2009-06-25
FR2843302A1 (fr) 2004-02-13
WO2004016248A2 (fr) 2004-02-26
CN1681480B (zh) 2010-04-14
EP1526841A2 (fr) 2005-05-04
US7833765B2 (en) 2010-11-16
AU2003274229B2 (en) 2009-05-21
US7485294B2 (en) 2009-02-03
KR20050083628A (ko) 2005-08-26
ES2327630T3 (es) 2009-11-02
EP1992336A2 (fr) 2008-11-19
DE60327772D1 (de) 2009-07-09
AU2003274229A1 (en) 2004-03-03
EP1526841B1 (fr) 2009-05-27
WO2004016248A8 (fr) 2004-05-21

Similar Documents

Publication Publication Date Title
BR0313469A (pt) Forma galêmica para a liberação cólica de princìpios ativos
BR0109378A (pt) Pelìculas oralmente consumìveis de rápida dissolução contendo uma resina de permuta de ìon como um agente de mascaramento de sabor
JP2024009904A (ja) トリガーパルス薬物放出を有する胃内滞留型raft形成システムを含む放出調節薬物粉末組成物
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
ES2196556T3 (es) Formulacion en granulos para el tratamiento del tracto intestinal.
BR9901782A (pt) Forma para dosagem de nefazodona.
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
WO2007036952A3 (en) Novel sustained release dosage form
TW200510006A (en) Fast dissolving orally consumable films containing a sweetener
CL2009002073A1 (es) Composicion farmaceutica solida para la liberacion controlada de un agente activo activo en el tracto gastrointestinal que comprende al menos un agente acido con solubilidad de menos de 0,3 mg/ml en solucion acuosa a un ph alrededor del pka del agente acido, un polimero hidrofilo, un alcanizador; uso en trastornos cardiovasculares.
WO2008007224A3 (en) Foamable suspension gel
ATE541562T1 (de) Ibuprofen-suspension
WO2004071374A3 (en) Once a day orally administered pharmaceutical compositions
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
GEP20074254B (en) Agent for treatment of joint disease
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
RU2006131594A (ru) Гликозидное пролекарство 5-аминосалициловой кислоты
JP2004505922A5 (pt)
JP2011516544A5 (pt)
BRPI0415232A (pt) uso de xenÈnio com hipotermia para tratar asfixia neonatal
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
WO2004071156A3 (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms
RU2007105450A (ru) Лечение и профилактика заболеваний и инфекций свиней и домашней птицы
BR0112830A (pt) Medicamento destinado especialmente a combater as disfunções sexuais
MXPA01007210A (es) Agente para el tratamiento de enfermedad de parkinson que comprende un agente que mejora la funcion del astrocito como ingrediente activo.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]

Free format text: DESLOCAR CARACTERIZADO POR, ELIMINAR ALGUMAS REIVINDICACOES, INSUFICIENCIA DESCRITIVA (ART. 24), FALTA DE CLAREZA DAS REIVINDICACOES (ART. 25), REIV. NAO FUNDAMENTADA NO REL. DESCRITIVO (ART. 25)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements